Saturday, September 6, 2025
  • Login
Forbes 40under40
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle
No Result
View All Result
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle
No Result
View All Result
Forbes 40under40
No Result
View All Result
Home Leadership

Cordlife jumps 48% to S$0.23 on partial offer from Thai-listed Medeze

by Yurie Miyazawa
in Leadership
Cordlife jumps 48% to Salt=
Share on FacebookShare on Twitter


The stem cell company is seeking to acquire about 25.6 million shares at S$0.25 apiece

[SINGAPORE] Shares of Cordlife surged by over 48 per cent on Thursday (May 15), after the company lifted its trading halt earlier in the morning, which had been put in place on Tuesday.

This came after a voluntary conditional cash partial offer from Medeze Treasury – a wholly owned subsidiary of Thai-listed stem cell company Medeze Group – was made for a 10 per cent stake in Cordlife.

The private cord-blood bank requested to lift its trading halt at 10.34 am on Thursday, which took effect at 11.15 am. By 11.24 am, its share price had increased by S$0.065 to S$0.22, from S$0.155.

As at 1.54 pm, Cordlife’s shares had risen 48.4 per cent or S$0.075 to S$0.23. At 2.06 pm, it fell slightly to S$0.225, up 45.2 per cent or S$0.07.

Medeze Treasury is seeking to acquire about 25.6 million shares at an offer price of S$0.25 apiece. As at Tuesday, the Medeze subsidiary holds nearly 1.7 million shares, which is close to 0.7 per cent of the voting rights in Cordlife.

The move by Medeze is its first step into the Singapore market, as the company seeks to explore business opportunities with Cordlife.

Assuming that the offer becomes unconditional and there are no changes to the number of shares up for offer, the resultant direct shareholding of Medeze Treasury in Cordlife shall be around 10.7 per cent of the shares (excluding treasury shares).

Earlier in March, Cordlife sunk into the red with a net loss of S$6.3 million for its second half ended Dec 31, 2024, compared with a net profit of S$1.3 million in the previous corresponding period. This was mainly due to the fallout from lapses discovered in the storage of the company’s cord-blood units two years ago.

Copyright SPH Media. All rights reserved.

Tags: CordlifeJumpsMedezeOfferpartialS0.23Thailisted
Yurie Miyazawa

Yurie Miyazawa

Next Post
UK insurer Aviva reports 9% rise in Q1 general insurance premiums

UK insurer Aviva reports 9% rise in Q1 general insurance premiums

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.

 
 
 
 

NEWS

  • Forbes Magazine
  • Technology
  • Innovation
  • Money
  • Leadership
  • Real Estate
  • Lifestyle
Instagram Facebook Youtube

© 2025 Forbes 40under40. All Rights Reserved.

  • About Us
  • Advertise
  • Contact Us
No Result
View All Result
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle

© 2024 Forbes 40under40. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In